Praemium Ltd

Strong FY 18 performance: Praemium Ltd.’s (ASX: PPS) stock has risen 43.11% in three months as on August 16, 2018 as the company for FY18 delivered 35% rise in FUA to $8.3 billion, 22% growth in revenue and other income to $43.2 million and a 40% increase in the underlying EBITDA to $8.8 million on FY17. The company has witnessed 50% rise in gross asset inflows of $3.0 billion on FY17. Meanwhile, PPS is well placed for UK market as UK revenue and other income witnessed growth of 27%, which resulted in a 22% reduction in EBITDA losses to $1.7 million. International Funds under administration (FUA) rose up 20% over last year to $2.7 billion, with assets managed by Smart Investment Management increasing by 15% to $794 million. The revenue from Australia increased by 19% compared to FY2017. There is record inflows to the SMA investment platform, up 69% to $2.2 billion, which resulted in a 44% increase in SMA revenue in Australia. Additionally, the company has received regulatory approval to sell its Smartfund range directly to the Middle East markets as the local promoter. Based on the foregoing, we give a “Hold” recommendation on the stock at the current price of $ 1.00 (up 2% on August 17, 2018).
 

FY 18 Financial Performance (Source: Company Reports)
 

Neuren Pharmaceuticals Ltd

NEU and ACADIA signed an exclusive North American License Agreement: Neuren Pharmaceuticals Ltd.’s (ASX: NEU) stock continued to fall by 1.14% on August 17, 2018. Recently, the company and ACADIA Pharmaceuticals Inc. signed an exclusive North American License Agreement for the development and commercialization of trofinetide for Rett syndrome and other indications. NEU has retained the rights to develop and commercialize trofinetide for all indications outside of North America. As per the License Agreement, NEU will receive US $10 million upfront plus potential milestones of up to US $455 million and royalties. Further, ACADIA has planned to initiate a Phase 3 study of trofinetide for the treatment of Rett syndrome, which is a rare neurodevelopmental congenital CNS disorder, in the second half of 2019, after the completion of additional manufacturing activities. Meanwhile, NEU stock has fallen 53.53% in one month as on August 16, 2018. As of now, we give an “Expensive” recommendation on the stock at the current price of $ 1.3.
 

DigitalX Ltd

Joint Venture launching a weekly blockchain TV news program: DigitalX Ltd.’s (ASX: DCC) stock surged 8.70% on August 17, 2018 with change in sector-driven sentiments after the report on Blockchain Industry 2018-2025 Global Market Research has been released. On the other hand, DCC and its joint venture partner Multiplier has recently announced that their media joint venture ‘Coincast Media’ has planned to launch a weekly blockchain TV news program that will air on Sky News Business, Apple TV and The Wall Street Journal. Coincast Media (formerly known as Digital Multiplier), after being launched in May 2018, has delivered strong revenue growth with over $300,000 in revenues to date, and is now delivering decent profits from the media assets it holds, including the multipliercrypto.com news platform, the coin.org video tutorial platform and now, Coincast TV. DCC holds a 50% interest in Coincast Media. Moreover, Coincast TV show’s revenue will be generated through a mix of corporate sponsorships and sponsored content and the first show was planned to go on air on 10 August 2018. Meanwhile, DCC stock has fallen 30.30% in three months as on August 16, 2018 and is trading at a P/E of 7.88x. Based on the foregoing, we give a “Hold” recommendation on the stock at the current price of $0.125.

Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.